HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ARRY-371797

a p38 MAP kinase inhibitor

Also Known As:

ARRY-797

Networked: 5 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Polyamines: 3918
    - Diamines: 518
      - Ethylenediamines: 7
        ARRY-371797: 5
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - Indazoles: 179
        ARRY-371797: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indazoles: 179
      - ARRY-371797: 5

Experts

1.	Choi, Jason C: 1 article (10/2012)
2.	Homma, Shunichi: 1 article (10/2012)
3.	Iwata, Shinichi: 1 article (10/2012)
4.	Morrow, John: 1 article (10/2012)
5.	Muchir, Antoine: 1 article (10/2012)
6.	Worman, Howard J: 1 article (10/2012)
7.	Wu, Wei: 1 article (10/2012)

Related Diseases

1.	Dilated Cardiomyopathy (Cardiomyopathy, Congestive) 01/01/2023 - "Plain Language Summary of Publication of the safety and efficacy of ARRY-371797 in people with dilated cardiomyopathy and a faulty LMNA gene." 01/01/2023 - "This plain language summary describes the results of a study looking at the effects of a medicine called ARRY-371797 (also known as PF-07265803) in people with dilated cardiomyopathy (DCM for short) caused by a faulty LMNA gene. " 01/01/2023 - "Efficacy and Safety of ARRY-371797 in LMNA-Related Dilated Cardiomyopathy: A Phase 2 Study." 01/01/2023 - "Long-term effectiveness of ARRY-371797 in people with dilated cardiomyopathy and a faulty LMNA gene: a plain language summary." 01/01/2023 - "Patients with LMNA-related dilated cardiomyopathy in New York Heart Association class II-IIIA, on background heart failure treatment, received ARRY-371797 100 or 400 mg twice daily for 48 weeks. "
2.	Heart Failure 01/01/2023 - "Patients with LMNA-related dilated cardiomyopathy in New York Heart Association class II-IIIA, on background heart failure treatment, received ARRY-371797 100 or 400 mg twice daily for 48 weeks. "
3.	Fibrosis (Cirrhosis) 10/01/2012 - "Treatment of Lmna(H222P/H222P) mice with the p38α inhibitor ARRY-371797 prevented left ventricular dilatation and deterioration of fractional shortening compared with placebo-treated mice but did not block the expression of collagen genes involved in cardiac fibrosis. "

Related Drugs and Biologics

1.	Lamin Type A (Lamin A)
2.	p38 Mitogen-Activated Protein Kinases
3.	Biomarkers (Surrogate Marker)
4.	Collagen
5.	pro-brain natriuretic peptide (1-76)